The FDA is facing even more leadership changes as drug regulator Dr Richard Pazdur prepares to retire at the end of the month.

Immediate neuro-rehabilitative treatment following moderate or severe TBI is associated with reduced risk of Alzheimer disease.

Impaired kidney function is associated with increased circulating levels of most Alzheimer disease blood biomarkers.

Tai chi is an effective alternative approach for the long-term management of chronic insomnia in middle-aged and older adults.

The Food and Drug Administration has granted Breakthrough Therapy designation to zilganersen for the treatment of Alexander disease.

The FDA has approved Avance® (acellular nerve allograft-arwx) for the treatment of sensory nerve discontinuity.

Cancer related cognitive impairment in patients can stem from the cancer itself as well as the therapies used to treat it.

Pediatric concussion patterns vary by age, with children in different age groups showing different injury causes and symptoms.

For patients with schizoaffective disorders, coffee consumption within the recommended dose is associated with longer telomere length.

An FDA memo is creating controversy after an official said the COVID-19 vaccine may have played a role in the deaths of at least 10 children.

The FDA approved Itvisma gene therapy for patients aged 2 years and older with spinal muscular atrophy and confirmed SMN1 gene mutation.

Longer PTR times during thrombectomy significantly increase the likelihood of death or hospice discharge and raise acute stroke care costs.